These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 18284457)
41. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538 [TBL] [Abstract][Full Text] [Related]
42. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome]. Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301 [TBL] [Abstract][Full Text] [Related]
43. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646 [TBL] [Abstract][Full Text] [Related]
44. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Georgiou G; Karali V; Zouvelou C; Kyriakou E; Dimou M; Chrisochoou S; Greka P; Dufexis D; Vervesou E; Dimitriadou E; Efthymiou A; Petrikkos L; Dima K; Lilakos K; Panayiotidis P Br J Haematol; 2006 Aug; 134(3):302-6. PubMed ID: 16787503 [TBL] [Abstract][Full Text] [Related]
45. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Cabello AI; Collado R; Ruiz MA; Martínez J; Navarro I; Ferrer R; Sosa AM; Carbonell F Leuk Res; 2005 Apr; 29(4):365-70. PubMed ID: 15725469 [TBL] [Abstract][Full Text] [Related]
46. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483 [TBL] [Abstract][Full Text] [Related]
47. Myelodysplastic syndromes in patients younger than age 50. Kuendgen A; Strupp C; Aivado M; Hildebrandt B; Haas R; Gattermann N; Germing U J Clin Oncol; 2006 Dec; 24(34):5358-65. PubMed ID: 17088566 [TBL] [Abstract][Full Text] [Related]
48. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes. Wang H; Wang X; Xu X; Lin G Ann Hematol; 2010 Jul; 89(7):671-9. PubMed ID: 20179929 [TBL] [Abstract][Full Text] [Related]
49. Myelodysplastic syndromes (MDS) in Central Africans. Mukiibi JM; Paul B Trop Geogr Med; 1994; 46(1):17-9. PubMed ID: 8165730 [TBL] [Abstract][Full Text] [Related]
50. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS. Slovak ML; O'Donnell M; Smith DD; Gaal K Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067 [TBL] [Abstract][Full Text] [Related]
51. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662 [TBL] [Abstract][Full Text] [Related]
52. [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome]. Aul C; Germing U; Gattermann N; Söhngen D; Heyll A Dtsch Med Wochenschr; 1996 Sep; 121(37):1113-8. PubMed ID: 8925725 [TBL] [Abstract][Full Text] [Related]
53. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338 [TBL] [Abstract][Full Text] [Related]
54. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Irons RD; Wang X; Gross SA; Bao L; Ryder J; Chen Y; Chen H; Sun H; Zhou J; Ji M; Du X; Fu H; Lin G Leuk Res; 2006 Jul; 30(7):769-75. PubMed ID: 16337268 [TBL] [Abstract][Full Text] [Related]
55. The myelodysplastic syndromes: classification and prognosis. Komrokji R; Bennett JM Curr Hematol Rep; 2003 May; 2(3):179-85. PubMed ID: 12901338 [TBL] [Abstract][Full Text] [Related]
59. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil. Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432 [TBL] [Abstract][Full Text] [Related]
60. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. Breccia M; Latagliata R; Cannella L; Carmosino I; De Cuia R; Frustaci A; Stefanizzi C; Santopietro M; Alimena G Leuk Res; 2009 Mar; 33(3):391-4. PubMed ID: 18676015 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]